Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit)

v3.21.2
Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2019 $ 0 $ 495 $ (8,055) $ (7,560)
Balance (in shares) at Dec. 31, 2019 2,852,485      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock in exchange for in-process research and development $ 0 2,126 0 2,126
Issuance of common stock in exchange for in-process research and development (in shares) 891,422      
Share-based compensation $ 0 61 0 61
Net and comprehensive loss 0 0 (3,088) (3,088)
Balance at Mar. 31, 2020 $ 0 2,682 (11,143) (8,461)
Balance (in shares) at Mar. 31, 2020 3,743,907      
Balance at Dec. 31, 2019 $ 0 495 (8,055) (7,560)
Balance (in shares) at Dec. 31, 2019 2,852,485      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net and comprehensive loss       (4,692)
Balance at Jun. 30, 2020 $ 0 3,969 (12,747) (8,778)
Balance (in shares) at Jun. 30, 2020 3,743,907      
Balance at Mar. 31, 2020 $ 0 2,682 (11,143) (8,461)
Balance (in shares) at Mar. 31, 2020 3,743,907      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Gain on note extinguishment $ 0 971 0 971
Share-based compensation 0 316 0 316
Net and comprehensive loss 0 0 (1,604) (1,604)
Balance at Jun. 30, 2020 $ 0 3,969 (12,747) (8,778)
Balance (in shares) at Jun. 30, 2020 3,743,907      
Balance at Dec. 31, 2020 $ 1 19,207 (32,675) (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Reclassification of Series A warrant liability to equity $ 0 61,793 0 61,793
Share-based compensation $ 0 494 0 494
Share-based compensation (in shares) 40,000      
Exercise of stock options $ 0 10 0 10
Exercise of stock options (in shares) 7,386      
Net and comprehensive loss $ 0 0 (39,014) (39,014)
Balance at Mar. 31, 2021 $ 1 81,504 (71,689) 9,816
Balance (in shares) at Mar. 31, 2021 10,929,881      
Balance at Dec. 31, 2020 $ 1 19,207 (32,675) (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net and comprehensive loss       (46,150)
Balance at Jun. 30, 2021 $ 2 101,376 (78,825) 22,553
Balance (in shares) at Jun. 30, 2021 16,891,855      
Balance at Mar. 31, 2021 $ 1 81,504 (71,689) 9,816
Balance (in shares) at Mar. 31, 2021 10,929,881      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock and warrants in connection with registered direct offering $ 1 14,999 0 15,000
Issuance of common stock and warrants in connection with registered direct offering (in shares) 3,076,923      
Issuance of common stock in connection with the at-the-market program $ 0 4,067   4,067
Issuance of common stock in connection with the at-the-market program (in shares) 900,943      
Issuance of common stock in connection with settlement with investors $ 0 1,614 0 1,614
Issuance of common stock in connection with settlement with investors (in shares) 350,000      
Issuance costs $ 0 (1,271)   (1,271)
Share-based compensation $ 0 463 0 463
Share-based compensation (in shares) 4,474      
Exercise of Series B warrants $ 0 0 0 0
Exercise of Series B warrants (in shares) 1,629,634      
Exercise of stock options (in shares) 0      
Net and comprehensive loss $ 0 0 (7,136) (7,136)
Balance at Jun. 30, 2021 $ 2 $ 101,376 $ (78,825) $ 22,553
Balance (in shares) at Jun. 30, 2021 16,891,855